See more : Auri, Inc. (AURI) Income Statement Analysis – Financial Results
Complete financial analysis of Corcept Therapeutics Incorporated (CORT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corcept Therapeutics Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Surya Semesta Internusa Tbk (SSIA.JK) Income Statement Analysis – Financial Results
- Dhipaya Group Holdings Public Company Limited (TIPH.BK) Income Statement Analysis – Financial Results
- Pharvaris N.V. (PHVS) Income Statement Analysis – Financial Results
- Origin Materials, Inc. (ORGN) Income Statement Analysis – Financial Results
- Neodecortech S.p.A. (NDT.MI) Income Statement Analysis – Financial Results
Corcept Therapeutics Incorporated (CORT)
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 482.38M | 401.86M | 365.98M | 353.87M | 306.49M | 251.25M | 159.20M | 81.32M | 50.29M | 26.55M | 10.36M | 3.31M | 0.00 | 0.00 | 29.00K | 209.00K | 482.00K | 294.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.48M | 5.39M | 5.28M | 5.58M | 5.50M | 5.22M | 3.55M | 2.06M | 1.36M | 882.00K | 143.00K | 91.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 475.89M | 396.47M | 360.70M | 348.29M | 300.98M | 246.03M | 155.65M | 79.26M | 48.93M | 25.67M | 10.21M | 3.22M | 0.00 | 0.00 | 29.00K | 209.00K | 482.00K | 294.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 98.66% | 98.66% | 98.56% | 98.42% | 98.20% | 97.92% | 97.77% | 97.47% | 97.29% | 96.68% | 98.62% | 97.25% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 184.35M | 130.99M | 113.86M | 114.76M | 89.02M | 75.25M | 40.38M | 23.84M | 15.42M | 18.37M | 20.47M | 14.07M | 21.00M | 18.95M | 14.40M | 14.15M | 7.86M | 20.83M | 17.07M | 11.55M | 8.11M | 13.26M | 5.39M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.33M | 8.49M | 5.88M | 5.75M | 4.87M | 5.04M | 4.08M | 4.49B | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.49B | 0.00 | 0.00 | 0.00 |
| SG&A | 184.26M | 152.85M | 122.36M | 105.33M | 100.36M | 81.29M | 62.42M | 45.24M | 36.95M | 34.92M | 31.24M | 25.41M | 11.33M | 8.49M | 5.88M | 5.75M | 4.87M | 5.04M | 4.08M | 4.49M | 1.89M | 5.53M | 2.62M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.44M | 6.59M | 4.33M | 4.39M | 4.02M | 4.03M | 3.29M | 3.02B | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 368.61M | 283.84M | 236.22M | 220.09M | 189.38M | 156.54M | 102.79M | 69.08M | 52.37M | 53.29M | 51.71M | 39.49M | 32.33M | 27.44M | 20.28M | 19.90M | 12.73M | 25.88M | 21.16M | 16.04M | 9.99M | 18.80M | 8.01M |
| Cost & Expenses | 375.09M | 289.22M | 241.50M | 225.67M | 194.88M | 161.75M | 106.35M | 71.14M | 53.73M | 54.17M | 51.85M | 39.58M | 32.33M | 27.44M | 20.28M | 19.90M | 12.73M | 25.88M | 21.16M | 16.04M | 9.99M | 18.80M | 8.01M |
| Interest Income | 17.28M | 3.56M | 529.00K | 3.40M | 5.07M | 2.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.56M | 0.00 | 0.00 | 5.07M | 2.66M | 49.00K | 2.04M | 2.97M | 3.76M | 4.52M | 1.78M | 3.00K | 1.50M | 101.00K | 944.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.04M | 2.97M | 3.07M | 2.24M | 2.17M | 236.00K | 106.00K | 87.00K | 155.00K | 141.00K | 74.00K | 27.00K | 3.00K | 6.00K | 10.00K | 12.00K | 13.00K | 14.00K | 704.00K | 1.61M | 22.55K | 0.00 | 0.00 |
| EBITDA | 108.32M | 112.63M | 124.48M | 130.44M | 113.78M | 89.73M | 52.96M | 10.27M | -3.29M | -27.48M | -41.42M | -36.25M | -32.35M | -25.96M | -20.25M | -19.69M | -12.25M | -25.58M | -20.09M | -15.47M | -9.97M | -18.80M | -8.01M |
| EBITDA Ratio | 22.46% | 28.03% | 34.01% | 36.23% | 36.41% | 35.62% | 33.20% | 12.62% | -6.54% | -103.49% | -399.94% | -1,096.01% | 0.00% | 0.00% | -69,734.48% | -8,785.17% | -2,534.44% | -8,693.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 107.28M | 112.63M | 124.48M | 128.20M | 111.61M | 89.50M | 52.86M | 10.18M | -3.44M | -27.62M | -41.50M | -36.27M | -32.33M | -27.44M | -20.25M | -19.69M | -12.25M | -25.58M | -21.16M | -16.04M | -9.99M | -18.80M | -8.01M |
| Operating Income Ratio | 22.24% | 28.03% | 34.01% | 36.23% | 36.41% | 35.62% | 33.20% | 12.52% | -6.85% | -104.02% | -400.66% | -1,096.82% | 0.00% | 0.00% | -69,827.59% | -9,420.57% | -2,540.46% | -8,701.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.28M | 3.56M | 529.00K | 3.40M | 5.07M | 2.66M | -49.00K | -2.04M | -2.97M | -3.76M | -4.52M | -1.78M | -22.00K | 1.47M | 84.00K | -372.00K | 672.00K | 709.00K | 1.07M | 510.35K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 124.56M | 116.19M | 125.01M | 131.60M | 116.68M | 92.15M | 52.81M | 8.14M | -6.41M | -31.38M | -46.01M | -38.05M | -32.35M | -25.97M | -20.17M | -20.06M | -11.57M | -24.87M | -20.09M | -15.53B | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 25.82% | 28.91% | 34.16% | 37.19% | 38.07% | 36.68% | 33.17% | 10.01% | -12.74% | -118.20% | -444.25% | -1,150.53% | 0.00% | 0.00% | -69,537.93% | -9,598.56% | -2,401.04% | -8,460.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 18.42M | 14.77M | 12.49M | 25.59M | 22.50M | 16.74M | -76.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.00K | -1.47M | -84.00K | 372.00K | -672.00K | -709.00K | -1.07M | -510.35K | -182.23K | 18.50M | 7.45M |
| Net Income | 106.14M | 101.42M | 112.51M | 106.01M | 94.18M | 75.41M | 129.12M | 8.14M | -6.41M | -31.38M | -46.01M | -38.05M | -32.35M | -25.97M | -20.17M | -20.06M | -11.57M | -24.87M | -20.09M | -15.53M | -9.81M | -18.50M | -7.45M |
| Net Income Ratio | 22.00% | 25.24% | 30.74% | 29.96% | 30.73% | 30.01% | 81.11% | 10.01% | -12.74% | -118.20% | -444.25% | -1,150.53% | 0.00% | 0.00% | -69,537.93% | -9,598.56% | -2,401.04% | -8,460.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 1.02 | 0.95 | 0.97 | 0.92 | 0.82 | 0.60 | 1.14 | 0.07 | -0.06 | -0.31 | -0.46 | -0.41 | -0.39 | -0.38 | -0.38 | -0.43 | -0.34 | -1.09 | -0.89 | -0.84 | -1.13 | -2.75 | -1.39 |
| EPS Diluted | 0.94 | 0.87 | 0.89 | 0.85 | 0.77 | 0.60 | 1.04 | 0.07 | -0.06 | -0.31 | -0.46 | -0.41 | -0.39 | -0.38 | -0.38 | -0.43 | -0.34 | -1.09 | -0.89 | -0.84 | -1.13 | -2.75 | -1.39 |
| Weighted Avg Shares Out | 103.56M | 106.79M | 115.65M | 115.41M | 114.35M | 125.68M | 113.53M | 110.57M | 106.80M | 100.98M | 99.82M | 93.02M | 83.31M | 68.34M | 52.44M | 46.72M | 34.25M | 22.84M | 22.61M | 18.44M | 8.65M | 6.72M | 5.38M |
| Weighted Avg Shares Out (Dil) | 111.74M | 115.97M | 125.96M | 124.19M | 122.57M | 126.69M | 124.52M | 116.14M | 106.88M | 100.98M | 99.82M | 93.02M | 83.31M | 68.34M | 52.44M | 46.72M | 34.25M | 22.84M | 22.61M | 18.44M | 8.65M | 6.72M | 5.38M |
Corcept Therapeutics shares sink after losing patent infringement lawsuit against Teva
Corcept Therapeutics shares fell by more than a quarter on Tuesday morning after a court found against it in a patent infringement lawsuit filed against Teva Pharmaceuticals. A US District Court said Teva does not infringe any asserted claims of Corcept's...
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Corcept (CORT) Up 0.7% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to march to its own beat, the underlying innovation may offer an...
Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View
Corcept's (CORT) third-quarter 2023 earnings and revenues surpass estimates. The company raises the full-year revenue guidance for 2023.
Corcept Therapeutics Incorporated (CORT) Q3 2023 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q3 2023 Earnings Call Transcript November 1, 2023 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer, President and Director Sean...
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the...
Corcept Appoints Monica Tellado as President, Emerging Markets
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the...
Why Earnings Season Could Be Great for Corcept Therapeutics (CORT)
Corcept Therapeutics (CORT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
MENLO PARK, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the...
Source: https://incomestatements.info
Category: Stock Reports